Outcomes of patients treated with the everolimus-eluting stent versus the zotarolimus eluting stent in a consecutive cohort of patients at a tertiary medical center

Figures & data

Table 1 Demographic and clinical variables

	n	Zotarolimus	n	Everolimus	P value
Age (years)	197	66.9 ± 12.2	189	65.7 ± 11.4	0.300
Body mass index	197	30.5 ± 6.9	187	30.9 ± 6.6	0.587
Male (%)	133/197	67.5	126/190	66.3	0.829
New York Heart Association class (%)	197		189		0.208
No symptoms/Class I	155	78.7	158	83.6
Class II	23	11.7	26	13.8
Class III	7	3.6	3	1.6
Class IV	12	6.1	2	1.1
Prior percutaneous coronary intervention (%)	133/197	67.5	142/189	75.1	0.115
Prior coronary artery bypass surgery (%)	43/197	21.8	47/190	24.7	0.548
Previous myocardial infarction (%)	57/197	28.9	74/190	38.9	0.041
Family history of premature coronary disease (%)	97/197	49.2	75/186	40.3	0.082
Renal failure (%)	11/197	5.6	8/186	4.3	0.642
Peripheral vascular disease (%)	30/197	15.2	21/190	11.1	0.233
History of hypertension (%)	151/197	76.6	153/190	80.5	0.387
Cerebrovascular disease (%)	32/197	16.2	2/190	4.7	0.001
Hyperlipidemia (%)	166/197	84.3	161/190	84.7	1.000
History of smoking (current and ex-smoker, %)	129/197	65.5	121/189	64	0.831
Diabetes mellitus (%)	72/197	36.5	70/189	37	1.000

Table 2 Indications for angiography and coronary artery distribution

	Zotarolimus	Everolimus	P value
Indications for angiography (%)			0.979
Unstable angina/NSTEMI	43.5	49.8
STEMI	4.8	2.4
Abnormal perfusion test with symptoms	17.7	15.3
Abnormal perfusion test with no symptoms	6.7	6.2
Cardiomyopathy/ congestive heart failure	1.4	0.5
Staged intervention	23.4	23.9
Arrhythmias	1.4	0.9
Recent decrease in ejection fraction	0	1
Progressive dyspnea	1	0
Number of patients treated (n)	197	190
Number of vessels treated (n)*	270	306
Number of segments treated (n)**	403	479
Distribution of coronary artery disease (per number of vessels, %)			0.835
Right coronary artery	24.8	20.9
Left main stem	6.3	9.8
Left anterior descending artery	35.4	35.9
Ramus intermedius	4.4	4.6
Left circumflex	29.1	28.8

Notes:

* The following were considered vessels per patient and counted when treated: LAD, LCX, RI, RCA, and LM;

** The following segments were considered per vessel and counted when treated: LAD, proximal, mid, distal, diagonal 1 and 2; LCX, proximal, distal, obtuse marginal 1 and 2, and posterolateral branch 1 and 2 RCA, proximal, mid, distal, acute marginal, posterior descending artery, posterolateral 1 and 2. Disease in LM and RI was considered as one segment per vessel.

Abbreviations: STEMI, ST elevation myocardial infarction; NSTEMI, non-ST elevation myocardial infarction; RI, ramus intermedius; LCX, left circumflex; LM, left main stem; LAD, left anterior descending; RCA, right coronary artery.

Table 3 Angiographic and procedural variables

	Zotarolimus	Everolimus	P value
Per patient analysis	n = 197	n = 190
Ejection fraction (%)	59.7 ± 13.2 (n = 101)	51.5 ± 143 (n = 152)	0.001
Stents used per patient (n)	2.8 ± 1.8	2.9 ± 2.1	0.690
Length of disease treated per patient (mm)	54 ± 37.4	52.2 ± 43	0.698
Patients treated with restenotic lesions (%)	33.3	42.6	0.104
Percentage of patients with non-left main bifurcating disease (%)	45.6	50.8	0.422
Syntax (first 100 consecutive patient in each group)	19.6 ± 12.8	20.6 ± 13.6	0.592
Per vessel analysis	n = 270	n = 306
Stents used per vessel (n)	1.8 ± 1.2	1.8 ± 1.2	0.880
Length of disease treated per vessel (mm)	34.5 ± 25.2	32.4 ± 26.4	0.371
Per segment analysis	n = 403	n = 479
Pre lesion severity (%)	71.7 ± 25.1	84.5 ± 11.9	0.001
Post lesion severity (%)	0.2 ± 2	0	0.103
Diameter (mm)	2.8 ± 0.4	3 ± 0.5	0.001
Stents used per segment (n)	1.1 ± 0.5	1.2 ± 0.4	0.029
Length of disease treated per segment (mm)	20.9 ± 9.5	20.7 ± 12.6	0.777
Segments treated with restenotic lesions (%)	28.7	33.9	0.128
Ostial segments treated (%)	8.3	8.2	1.000

Figure 1 Kaplan-Meier curve showing target vessel failure survival for the Endeavor zotarolimus stent (solid line) versus the Everolimus stent (dashed line).

Abbreviation: TVF, target vessel failure.

Table 4 Patient outcomes

	Zotarolimus	Everolimus	P value
Duration of follow-up (days)	350.9 ± 55.8	344.6 ± 70.5	0.001
TLR per segment (%)	14.4	6.1	0.001
TLR per vessel (%)	17	7.9	0.002
TLR per patient (%)	20.6	8.9	0.003
TLR per segment (%)	16.7	9.5	0.002
TLR per vessel (%)	20.8	14.5	0.059
TLR per patient (%)	25.6	18.9	0.142
Target lesion failure (%)	22.6	11.7	0.003
Target vessel failure (%)	26.7	20.8	0.19
Stent thrombosis (%)			NA
Definite or probable	2.5	0
Possible	0.5	0.5
Patient on clopidogrel at definite or probable stent thrombosis event (%)	100	0	NA
Patient compliance when definite or probably stent thrombosis occurred (%)	100	0	NA
Percent of patients on clopidogrel on follow-up (%)	95.9	93.1	0.256
Percent of patients on aspirin on follow-up (%)	94.3	97.7	0.118
Death classification on follow-up (%)
No	94.9	96.8	NA
Non-cardiac	2.1	1.1
Unknown	1	0.5
Cardiac sudden death probable	1	0
Cardiac non-stent thrombosis	1	1.6
Acute non-ST elevation myocardial infarction, non-fatal (%)	3.6	1.1	0.176
Acute ST elevation myocardial infarction, non-fatal (%)	0	1.6	0.118

Abbreviations: NA, not applicable; TLR, Target lesion revascularization.